Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120
- PMID: 9420029
- PMCID: PMC164179
- DOI: 10.1128/AAC.41.12.2616
Sensitivity of human immunodeficiency virus to bicyclam derivatives is influenced by the three-dimensional structure of gp120
Abstract
The bicyclams are a new class of anti-human immunodeficiency virus (anti-HIV) compounds targeted at viral entry. From marker rescue experiments, it appears that the envelope gp120 glycoprotein plays an important role in the anti-HIV activity of the bicyclams. Bicyclam-resistant strains contain a number of amino acid changes scattered over the V2 to V5 region of gp120. Experiments aimed at estimating the relative importance of particular amino acid changes with regard to the overall resistance pattern are described. The sequences of some partially bicyclam-resistant virus strains, obtained during the resistance development process, were analyzed, and the corresponding 50% effective concentrations were determined. Selected mutations observed in bicyclam-resistant strains were introduced in the wild-type background by site-directed mutagenesis. In addition, some amino acids were back-mutated to their wild-type counterparts in an otherwise JM3100-resistant strain. The sensitivities of these mutant viruses to bicyclams were determined. Construction of chimeric viruses, carrying the V3 loop of JM3100-resistant virus in a wild-type HIV type 1 HXB2 background, enabled us to investigate the importance of the mutations in the V3 loop of JM3100-resistant virus. From the results described in the report, it can be concluded that single amino acid substitutions do not influence the observed resistance to JM3100. Also, the mutations in the V3 loop are not sufficient to engender even a partially resistant phenotype. We postulate that the overall conformation of gp120 determines the degree of sensitivity or resistance of HIV strains to bicyclams.
Similar articles
-
The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication.J Virol. 1996 Feb;70(2):689-96. doi: 10.1128/JVI.70.2.689-696.1996. J Virol. 1996. PMID: 8551604 Free PMC article.
-
The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding.Antiviral Res. 1996 Mar;29(2-3):209-19. doi: 10.1016/0166-3542(95)00837-3. Antiviral Res. 1996. PMID: 8739600
-
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.J Virol. 2004 Mar;78(6):2790-807. doi: 10.1128/jvi.78.6.2790-2807.2004. J Virol. 2004. PMID: 14990699 Free PMC article.
-
Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists.Mol Pharmacol. 2000 May;57(5):833-9. Mol Pharmacol. 2000. PMID: 10779364 Review.
-
The bicyclam AMD3100 story.Nat Rev Drug Discov. 2003 Jul;2(7):581-7. doi: 10.1038/nrd1134. Nat Rev Drug Discov. 2003. PMID: 12815382 Review.
Cited by
-
R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switch.J Virol. 2008 Jul;82(14):7089-99. doi: 10.1128/JVI.00570-08. Epub 2008 May 14. J Virol. 2008. PMID: 18480460 Free PMC article.
-
Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100.J Virol. 2008 Dec;82(23):11695-704. doi: 10.1128/JVI.01303-08. Epub 2008 Sep 17. J Virol. 2008. PMID: 18799588 Free PMC article.
-
ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.Antimicrob Agents Chemother. 2010 Oct;54(10):4487-92. doi: 10.1128/AAC.00359-10. Epub 2010 Jul 19. Antimicrob Agents Chemother. 2010. PMID: 20643898 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases